Selenopeptide Nanomedicine Activates Natural Killer Cells for Enhanced Tumor Chemoimmunotherapy

Selenopeptide Nanomedicine Activates Natural Killer Cells for Enhanced Tumor Chemoimmunotherapy

© 2022 Wiley-VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 34(2022), 17 vom: 01. Apr., Seite e2108167
1. Verfasser: Wei, Ziyu (VerfasserIn)
Weitere Verfasser: Yi, Yu, Luo, Zhen, Gong, Xiaoyun, Jiang, Yuxing, Hou, Dayong, Zhang, Li, Liu, Zimo, Wang, Mandi, Wang, Jie, Guo, Ruochen, Yang, Jinjun, Wang, Lei, Wang, Hao, Zhao, Yuliang
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article chemoimmunotherapy drug delivery programmable nanomedicine selenopeptide self-assembly Doxorubicin 80168379AG
LEADER 01000naa a22002652 4500
001 NLM336651244
003 DE-627
005 20231225232628.0
007 cr uuu---uuuuu
008 231225s2022 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.202108167  |2 doi 
028 5 2 |a pubmed24n1122.xml 
035 |a (DE-627)NLM336651244 
035 |a (NLM)35132688 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Wei, Ziyu  |e verfasserin  |4 aut 
245 1 0 |a Selenopeptide Nanomedicine Activates Natural Killer Cells for Enhanced Tumor Chemoimmunotherapy 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 28.04.2022 
500 |a Date Revised 28.04.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2022 Wiley-VCH GmbH. 
520 |a Chemoimmunotherapy using nanotechnology has shown great potential for cancer therapy in the clinic. However, uncontrolled transportation and synergistic responses remain challenges. Here, a self-assembled selenopeptide nanoparticle that strengthens tumor chemoimmunotherapy through the activation of natural killer (NK) cells by the oxidative metabolite of the selenopeptide is developed. With the advantages of the enzyme-induced size-reduction and the reactive-oxygen-species-driven deselenization, this selenopeptide is able to deliver therapeutics, e.g., doxorubicin (DOX), to solid tumors and further activate the NK cells in a programmed manner. Importantly, in vitro and in vivo results prove the mutual promotion between the DOX-induced chemotherapy and the selenopeptide-induced immunotherapy, which synergistically contribute to the improved antitumor efficacy. It is anticipated that the selenopeptide may provide a type of promising stimuli-responsive immune modulator for versatile biomedical applications 
650 4 |a Journal Article 
650 4 |a chemoimmunotherapy 
650 4 |a drug delivery 
650 4 |a programmable nanomedicine 
650 4 |a selenopeptide 
650 4 |a self-assembly 
650 7 |a Doxorubicin  |2 NLM 
650 7 |a 80168379AG  |2 NLM 
700 1 |a Yi, Yu  |e verfasserin  |4 aut 
700 1 |a Luo, Zhen  |e verfasserin  |4 aut 
700 1 |a Gong, Xiaoyun  |e verfasserin  |4 aut 
700 1 |a Jiang, Yuxing  |e verfasserin  |4 aut 
700 1 |a Hou, Dayong  |e verfasserin  |4 aut 
700 1 |a Zhang, Li  |e verfasserin  |4 aut 
700 1 |a Liu, Zimo  |e verfasserin  |4 aut 
700 1 |a Wang, Mandi  |e verfasserin  |4 aut 
700 1 |a Wang, Jie  |e verfasserin  |4 aut 
700 1 |a Guo, Ruochen  |e verfasserin  |4 aut 
700 1 |a Yang, Jinjun  |e verfasserin  |4 aut 
700 1 |a Wang, Lei  |e verfasserin  |4 aut 
700 1 |a Wang, Hao  |e verfasserin  |4 aut 
700 1 |a Zhao, Yuliang  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 34(2022), 17 vom: 01. Apr., Seite e2108167  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnns 
773 1 8 |g volume:34  |g year:2022  |g number:17  |g day:01  |g month:04  |g pages:e2108167 
856 4 0 |u http://dx.doi.org/10.1002/adma.202108167  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 34  |j 2022  |e 17  |b 01  |c 04  |h e2108167